Having demonstrated that RORγ-agonist-treated Tc17 and CAR T cells showed enhanced tumor killing in vitro, we next asked if these cells could confer better tumor regression in vivo after being adoptively transferred into tumor-bearing mice. This evidence concerns the gene RORC and neoplasm.